《Wednesday's First Moves: MRNA Downgrade, BA Jet Contract, JBL Earnings》Citigroup
MRNA 应予卖出；Citi 将其下调至卖出，目标价 80 美元（下行空间超过 60%），因癌症试验推动的 200% 涨幅已被充分定价，且估值假设了未来肿瘤领域的过度成功。
我们将 Moderna 视为一个“卖出”标的。花旗今天给予其“卖出”评级。此前 Moderna 近期表现强劲，得益于一些积极的试验结果。他们将其评级从“中性”下调至“卖出”。与此同时，他们上调了该股的目标价，但仅上调至 80。
这是从 60 上调而来。因此，在今天之前，他们的展望并不十分乐观。这意味着较昨日收盘水平有超过 60% 的潜在下跌空间。
We view Moderna as a "sell" product. Citigroup gave it a "sell" rating today. This comes after Moderna's recent strong performance, thanks to some positive trial results . They have downgraded its rating to "Sell" from " Neutral".
At the same time, they raised the target price for the stock, but only to 80. This is a rise from 60. So, their outlook wasn't very positive before today. This means a potential drop of more than 60% from yesterday's closing levels.